Diagnosis of Irritable Bowel Syndrome: Role of Potential Biomarkers

Abstract EN

Irritable bowel syndrome is a disorder diagnosed on symptom-based criteria without inclusion of any objective parameter measurable by known diagnostic methods.

Heterogeneity of the disorder and overlapping with more serious organic diseases increase uncertainty for the physician’s work and increase the cost of confirming the diagnosis.

This paper is an attempt to summarize the efforts to find adequate biomarkers for irritable bowel syndrome, which should shorten the time to diagnosis and reduce the cost.

Most of the reviewed papers were observational studies from secondary care institutions.

Since publication of the Rome III criteria in 2006, most recent studies use these for the recruitment of IBS patients.

This is a positive step forward as future studies should use the same criteria, facilitating comparison of their results.

Among the studied biomarkers, most evidence is provided for fecal calprotectin.

Cutoff values for fecal calprotectin have still to be investigated prior to inclusion in the irritable bowel syndrome diagnostic algorithm.